Nantes, February 2023
BioMAdvanced Diagnostics is extremely happy to announce that, in the perspective to start the industrial production of its 1st product (a subclinical rejection in vitro test for kidney transplanted patients), Eurofins Genomics, a trusted brand around the globe which provides leading expertise and technologies for the fast-growing diagnostic market, has accepted to deliver to us oligonucleotides under an OEM agreement that has just been signed.
The whole team wants to warmly thank Eurofins Genomics’ leadership and team for having been so supportive during the Design phase and for having been so startup friendly (i.e. fast, professional, down to earth and fun) in conducting the agreement elaboration and finalization.
BioMAdvanced Diagnostics expects to announce further agreements in its journey towards manufacturing. The 1st batches of production will be solely dedicated to the analytical and clinical validations processes that will lead to regulatory approval.
About BioMAdvanced Diagnostics
BioMAdvanced Diagnostics is a MedTech start-up based in Nantes, spinoff from the CR2TI (Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, INSERM – Nantes University) and from the University Hospital (CHU) of Nantes.
BioMAdvanced Diagnostics brings a real disruption in the field of Biomarkers related to the Immune System based on 20 years of academic translational research. Its main goal is to enable a truly personalized, preventive and predictive medicine which will greatly improve outcomes for the patient by providing unprecedented tools to clinicians.
The first applications will concern the improvement of kidney or lungs transplanted patients’ follow up. Two key benefits of its solutions : minimally invasive solutions for the patient and very substantial cost reductions for the Health Systems.